Cobas HIV-1 assay is CE mark approved in the EU for Cobas 4800 system- Roche

Roche announced the commercial availability of the cobas HIV-1 assay in countries accepting the CE mark. These new molecular diagnostic assay increase the available menu on the cobas 4800 System.

Cobas HIV-1 is built upon the dual-target assay design from Roche. The test simultaneously amplifies and detects two separate regions of the HIV-1 genome, which are not subject to selective drug pressure, allowing for more reliable results to confidently and effectively quantify the amount of HIV-1 RNA in a patient's blood. It is one of three new virology assays that can run simultaneously on the cobas 4800 System with two different sample processing volumes for HIV-1 and HCV (200 µL and 400 µL) and only 400 µL for HCV GT streamlining workflow while increasing flexibility for patient sample management.